• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CERo Therapeutics Holdings Inc.

    7/28/25 5:01:55 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CERO alert in real time by email
    S-8 1 ea0250116-s8_cero.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on July 28, 2025

    Registration No. 333-        

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8 

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

     

    CERO THERAPEUTICS HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   81-4182129

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    201 Haskins Way, Suite 230

    South San Francisco, CA 94080

    (215) 731-9450 

    (Address of Principal Executive Offices)

     

    CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan

    CERo Therapeutics Holdings, Inc. 2024 Employee Stock Purchase Plan

    (Full Title of the Plans)

     

     

     

    Chris Ehrlich

    Chief Executive Officer

    CERo Therapeutics Holdings, Inc.

    201 Haskins Way, Suite 230

    South San Francisco, CA 94080

    Telephone: (215) 731-9450

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    Stephen M. Davis

    Jeffrey A. Letalien

    Goodwin Procter LLP

    The New York Times Building

    620 Eighth Avenue

    New York, New York 10018

    (212) 813-8800 

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    PART I.

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (this “Registration Statement”), is being filed by CERo Therapeutics Holdings, Inc. (the “Registrant”), for the purpose of registering an additional (1) 109,485 shares of the Registrant’s common stock, par value $0.0001 per share (“Common Stock”), issuable pursuant to the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”), and (2) 510 shares of Common Stock, issuable pursuant to the CERo Therapeutics Holdings, Inc. 2024 Employee Stock Purchase Plan (the “2024 ESPP”) (in each case as adjusted for each of the reverse stock split of 1-for-100 effected by the Registrant effective as of January 8, 2025 and the reverse stock split of 1-for-20 effected by the Registrant effective as of June 13, 2025), as additional shares of Common Stock issuable under each of the 2024 Plan and the 2024 ESPP for which shares of Common Stock have previously been registered pursuant to a Registration Statement on Form S-8 which has previously been filed and is effective. Accordingly, this Registration Statement on Form S-8 incorporates by reference the contents of the Registration Statement on Form S-8 (File No. 333-283698) filed with the Securities and Exchange Commission on December 9, 2024 by the Registrant, relating to the 2024 Plan and 2024 ESPP, except, in each case, for “Item 8. Exhibits.” 

     

    1

     

     

    PART II.

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    EXHIBIT INDEX 

     

    Exhibit
    No.
      Description
       
    4.1   Second Amended and Restated Certificate of Incorporation of CERo Therapeutics Holdings, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K/A, filed on February 27, 2024).
       
    4.2   Second Amended and Restated Bylaws of CERo Therapeutics Holdings, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K/A, filed on February 27, 2024). 
       
    5.1*   Opinion of Goodwin Procter LLP.
       
    23.1*   Consent of Wolf & Company, P.C.
       
    23.2*   Consent of Goodwin Procter LLP (included in Exhibit 5.1).
       
    24.1*   Power of Attorney (included on signature page of this Registration Statement).
       
    99.1   CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K/A, filed on February 27, 2024 (File No. 001-40877)). 
         
    99.2   CERo Therapeutics Holdings, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K/A, filed on February 27, 2024 (File No. 001-40877)).
       
    99.3  

    First Amendment to the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.4 to the Registrant’s Registration Statement on Form S-8, filed on December 9, 2024).

         
    99.4   Second Amendment to the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 99.5 to the Registrant’s Registration Statement on Form S-8, filed on December 9, 2024).
         
    99.5   Third Amendment to the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on May 29, 2025).
       
    107*   Filing Fee Table.

     

    * Filed herewith.

     

    II-1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of South San Francisco, State of California, on July 28, 2025.

     

      CERO THERAPEUTICS HOLDINGS, INC.
         
      By:

    /s/ Chris Ehrlich

      Name: Chris Ehrlich.
      Title: Chairman, Chief Executive Officer and Director

     

    POWER OF ATTORNEY AND SIGNATURES

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Chris Ehrlich and Andrew Kucharchuk as such person’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or any substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following person in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Chris Ehrlich   Chairman and Chief Executive Officer and Director   July 28, 2025
    Chris Ehrlich   (Principal Executive Officer)    
             
    /s/ Andrew Kucharchuk   Chief Financial Officer   July 28, 2025
    Andrew Kucharchuk   (Principal Financial and Accounting Officer)    
             
    /s/ Brian Atwood   Director   July 28, 2025
    Brian Atwood        
             
    /s/ Michael Byrnes   Director   July 28, 2025
    Michael Byrnes        
             
    /s/ Kathleen LaPorte   Director   July 28, 2025
    Kathleen LaPorte        
             
    /s/ Lindsey Rolfe   Director   July 28, 2025
    Lindsey Rolfe        
             
    /s/ Shami Patel   Director   July 28, 2025
    Shami Patel        

     

    II-2

     

     

    Get the next $CERO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CERO

    DatePrice TargetRatingAnalyst
    6/23/2025$30.00Hold → Buy
    D. Boral Capital
    More analyst ratings

    $CERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Laporte Kathleen

      4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

      6/2/25 5:09:45 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Byrnes Michael

      4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

      6/2/25 5:08:19 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Rolfe Lindsey

      4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

      6/2/25 5:06:49 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CERO
    SEC Filings

    See more
    • SEC Form EFFECT filed by CERo Therapeutics Holdings Inc.

      EFFECT - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

      7/30/25 12:15:24 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by CERo Therapeutics Holdings Inc.

      S-8 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

      7/28/25 5:01:55 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.

      424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

      7/25/25 4:05:40 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CERO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

      Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the second patient in the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia (AML).  The patient was dosed at the Sarah Cannon Research Institute (SCRI) at Colorado B

      7/31/25 8:10:00 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

      SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial's Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly. CERo CMO Robert Sikorski MD., PhD. noted, "The first patien

      6/23/25 8:15:00 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

      SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo's Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying

      6/17/25 8:15:00 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CERO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CERo Therapeutics upgraded by D. Boral Capital with a new price target

      D. Boral Capital upgraded CERo Therapeutics from Hold to Buy and set a new price target of $30.00

      6/23/25 8:00:37 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CERO
    Leadership Updates

    Live Leadership Updates

    See more
    • CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

      SOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) --   CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces its Board of Directors has appointed Chris Ehrlich as CEO.  Previously he held the position of Interim CEO. Mr. Ehrlich commented, "I believe that CERo presents multiple, significant opportunities to make an impact on the market and benefit a significant patient population with both sound science and an experienced team of professionals to drive successful execution. 

      12/6/24 9:00:00 AM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

      SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

      12/13/24 7:18:17 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CERo Therapeutics Holdings Inc.

      SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

      11/20/24 4:06:55 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

      SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

      11/20/24 4:01:41 PM ET
      $CERO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care